Why Tendons Are Studied Most Extensively
Tendon injuries are among the most clinically challenging in sports medicine and orthopedics. Tendons have limited blood supply and slow healing capacity. Surgical options are imperfect. This clinical need has made tendon healing one of the primary research targets for BPC-157.
The Achilles Tendon Studies
A series of rodent studies on BPC-157 and Achilles tendon healing is the most frequently cited evidence. These studies involved surgical transection of rat Achilles tendons followed by BPC-157 or control administration. BPC-157-treated animals consistently showed faster macroscopic healing, improved tendon continuity on histology, and better biomechanical properties in healed tissue compared to controls.
Proposed Mechanisms
Researchers have proposed several mechanisms for BPC-157’s observed tendon effects: upregulation of VEGF (vascular endothelial growth factor) promoting angiogenesis at the injury site, interaction with the nitric oxide system improving local blood flow, and activation of EGR-1 (early growth response protein 1) which regulates tendon-associated genes.
What This Means for Patients
The tendon research is compelling enough that physicians experienced in sports medicine and functional medicine use BPC-157 for tendon injury patients. The absence of human trials means that dosing, optimal protocol duration, and expected outcomes in humans are based on clinical experience rather than controlled trials. Physician oversight matters particularly for this reason.